Reuters, Friday, November 14, 1997 at 17:07
BOSTON, Nov 14 (Reuters) - Nitinol Medical Technologies Inc
said Friday said that two studies involving its product
CardioSEAL have shown positive results.
It said that in a multi-center clinical trial for the
device, which is designed to close holes in the heart, 96
percent out of 82 patients implanted with the product showed a
"clinically successful result."
The result of the study was reported by Evan Zahn, a doctor
at Miami's Children's Hospital, Miami, Fla., in a talk at the
annual meeting of the American Heart Association, it said.
The preliminary data suggests that CardioSEAL is a "safe
and effective" device for transcatheter to close atrial septal
defects, Nitinol quoted Zahn as saying.
In another study, Nitinol said that Dr. Kathy Jenkins, in a
report on a study on the use of CardioSEAL for high risk
patients sponsored by Children's Hospital in Boston, said
findings suggest that the device "will be an important
alternative to surgery for high risk patients."
Thomas Tully, Nitinol president and chief executiv, said
the company was encouraged by clinical experience on the use of
thr device. He said that further investigations of the device
are ongoing in North America.
CardioSEAL is commercially available in most countries
elsewhere in the world, he said.
Copyright 1997, Reuters News Service |
